Replies to post #209401 on Biotech Values

[jq1234]

Look like BMY is hedging in 1st line RCC:


Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma

Companies intend to initiate pivotal trial evaluating CABOMETYX™ (cabozantinib) with Opdivo® (nivolumab) alone or in combination with Yervoy® (ipilimumab) in first-line renal cell carcinoma

Planning additional studies in bladder cancer and hepatocellular carcinoma

http://www.businesswire.com/news/home/20170227005356/en/